Biopharma News: Arena Pharmaceuticals, Inc. (ARNA)’s Update, New VIVUS, Inc. (VVUS) Deal & More

Page 2 of 2

Johnson & Johnson’s Stock Looks Too Healthy (TheStreet)
While I have always liked health-care giant Johnson & Johnson (NYSE:JNJ), it’s hard to recommend taking a position at these levels. The stock is already up more than 22% on the year and trading at a price/earnings ratio that is more than twice that of rival Abbott Laboratories (NYSE:ABT) and eight points higher than Pfizer Inc. (NYSE:PFE). …Now, there are new worries about Johnson & Johnson (NYSE:JNJ)’s organic growth. While I do believe these fears are overblown, JNJ’s first-quarter report didn’t exactly reduce that level of distress, even though the stock price presumes “all is well.”

Cancer-Causing Agent Found in Johnson & Johnson Baby Powders (IBTimes)
The famous cosmetic brand manufacturer Johnson & Johnson (NYSE:JNJ) loses its license in India due to an ordered case by the Food and Drug Administration after 15 batches of baby powder products were found sterilized by an irritant and cancer-causing component. Food and Drug Administration or FDA cancelled the licence of Johnson & Johnson (NYSE:JNJ) India to produce the product at their Mulund plant. The order will come to effect on June 24, 2013 and according to the FDA officials, ethylene oxide was found in 15 batches of baby powder produced which is labelled as carcinogenic and an irritant.

Orexigen Therapeutics praises new research report on obesity prevention policies (News-Medical)
Regarding the report “The Long Term Returns of Obesity Prevention Policies” unveiled this week by the Campaign to End Obesity (CEO), Orexigen Therapeutics, Inc. (NASDAQ:OREX) issued the following statement: Orexigen Therapeutics, Inc. (NASDAQ:OREX) commends CEO as well as the author of the report, Alex Brill, and the Robert Wood Johnson Foundation (RWJF) who funded the report, for this new research illustrating the importance of long-term budget impact analyses on preventive health policies, specifically those aimed at obesity. With obesity contributing over $200 billion annually to healthcare spending, Orexigen Therapeutics, Inc. (NASDAQ:OREX) agrees that policymakers need thorough budgetary analyses that capture short and long-term impacts of obesity policy.




Page 2 of 2